Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

At the same time, the final phase continues for a trial of Vertex’s zimislecel (formerly VX-880), a cell-based therapy that does require immunosuppression to protect the immune system from rejecting ...

Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […] Vertex plans to submit regulatory filings seeking approval for ...

Despite this setback, Vertex’s zimislecel program for T1D is progressing positively, with plans for global regulatory submissions by 2026. Additionally, Vertex’s non-opioid pain medication ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate beta cells in patients with early type 1 diabetes. The City of Hope Medical ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the ...

Zimislecel, Vertex’s islet cell therapy, remains on track for Phase 3 completion in 2025, with regulatory submissions expected in 2026. China’s new tariffs just reignited the same market ...